BeOne Medicines Ltd
06160
Company Profile
Business description
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.
Contact
c/o BeOne Medicines I GmbH
Aeschengraben 27
21st Floor
Basel4051
CHET: +41 616851900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11,000
Stocks News & Analysis
stocks
Unwarranted drop in ASX share
Jittery investors misinterpret an audit for an existential crisis.
stocks
After earnings, is Disney stock a buy, a sell, or fairly valued? -
Following the highly anticipated announcement of a new CEO, here’s what we think of Disney.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,281.80 | 97.30 | 1.06% |
| CAC 40 | 8,323.28 | 49.44 | 0.60% |
| DAX 40 | 25,014.87 | 293.41 | 1.19% |
| Dow JONES (US) | 50,135.87 | 20.20 | 0.04% |
| FTSE 100 | 10,386.23 | 16.48 | 0.16% |
| HKSE | 27,285.00 | 101.85 | 0.37% |
| NASDAQ | 23,238.67 | 207.46 | 0.90% |
| Nikkei 225 | 57,699.09 | 1,335.15 | 2.37% |
| NZX 50 Index | 13,507.28 | 60.91 | 0.45% |
| S&P 500 | 6,964.82 | 32.52 | 0.47% |
| S&P/ASX 200 | 9,014.80 | 98.80 | 1.11% |
| SSE Composite Index | 4,139.24 | 10.86 | 0.26% |